GENFIT Reports First Half-Year 2023 Financial Results and

Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in...

Related Keywords

United Kingdom ,France ,Seal Rock ,Massachusetts ,United States ,Zurich ,Züsz ,Switzerland ,Paris ,France General ,Cambridge ,Cambridgeshire ,French ,Sakina Sayah Jeanne ,Pascal Prigent ,Tom Huijbers ,Sandra Silvestri ,Steven Hildemann ,Research Tax Credit ,Financiers French Financial Markets Authority ,Uncertainties Of The Company ,Drug Administration ,Euronext ,Nasdaq ,Phepatology Communications ,Celloram Inc ,Company Annual Shareholder Meeting ,Patient Affairs ,Research Translational Science ,Board Of Directors The Company ,Cash Flow Of The Group ,Us Securities Exchange Commission ,Head Of Global Medical Affairs ,Service Transition Agreement ,Group Cash ,Transition Services Agreement ,International Financial Reporting Standards ,Research As ,European Medicines Agency ,Exchange Commission ,Chronic Liver Failure ,Investigational New Drug ,Digestive Disease Week ,Seal Rock Therapeutics ,Reactive Oxygen Species ,Hepatic Encephalopathy ,Urea Cycle Disorders ,Organic Acidemias ,Inborn Errors ,Non Invasive Test ,Annual Shareholder Meeting ,Executive Vice President ,Chief Medical Officer ,Global Medical Affairs ,Patient Safety ,Executive Vice President Research ,Translational Science ,European Medicines ,Orphan Drug Designation ,License Agreement ,Transition Services ,Consolidated Statement ,Year Business ,Financial Report ,Registration Document ,French Autorit ,Des March ,Consolidated Financial Results ,Condensed Consolidated Statements ,Financial Position ,Cash Flow ,Half Year Business ,Cash Flows ,Primary Biliary Cholangitis ,Nasdaq Global Select Market ,Private Securities Litigation Reform Act ,French Financial Markets Authority ,Paris Stock Exchange Gnft ,Genfit Sa ,